GÖTTINGEN, Germany,
Nov. 25, 2021 /PRNewswire/ -- The
life science company Sartorius is investing around 270 million euros, some 300 million U.S. dollars, through the end of 2024
in expanding its activities in South
Korea. In the country's biopharma hub Songdo in Incheon, the
company plans to launch cell culture media production and to
assemble sterile systems for efficient and flexible manufacturing
of biopharmaceuticals, among other operations. This investment
responds to the dynamic development of the South Korean market
as well as of further Asian markets.
"The development of the biopharmaceutical industry in
Asia and, in particular,
South Korea, has entered a new phase characterized by a high
innovation and investment pace on the part of our customers. With
our significant investments in Songdo, we will be increasing
capacities, moving production operations closer to our customers in
the region and substantially accelerating our delivery speed," said
Sartorius Executive Board Chairman and CEO Joachim Kreuzburg on Thursday in
South Korea after meeting with ministers of the country's
government.
Construction of the company's facilities on the property site
covering some 25,000 square meters, or close to 270,000 square
feet, will include an application center with laboratories as well
as several buildings for manufacturing and logistics. In total, new
jobs for approximately 750 people will be created there. In
addition, Sartorius' existing activities for service as well as
marketing and sales will relocate to the new site under
development, which offers space for further extensions.
Construction work at the site is slated to begin in the coming
year, and production operations are scheduled to start by the end
of 2024.
Sartorius has been operating a sales and service office in
South Korea for more than 30
years. Currently, more than 180 people work at this location for
Sartorius.
A profile of Sartorius
The Sartorius Group is a leading international partner of life
science research and the biopharmaceutical industry. With
innovative laboratory instruments and consumables, the Group's Lab
Products & Services Division concentrates on serving the needs
of laboratories performing research and quality control at pharma
and biopharma companies and those of academic research institutes.
The Bioprocess Solutions Division with its broad product portfolio
focusing on single-use solutions helps customers to manufacture
biotech medications and vaccines safely and efficiently. The Group
has been annually growing by double digits on average and has been
regularly expanding its portfolio by acquisitions of complementary
technologies. In fiscal 2020, the company earned sales revenue of
some 2.34 billion euros. At the end of 2020, nearly 11,000
people were employed at the Group's approximately
60 manufacturing and sales sites, serving customers around the
globe. Follow Sartorius on Twitter and on LinkedIn.
Contact
Timo Lindemann
Press Spokesman
+49 (0)551.308.4724
timo.lindemann@sartorius.com
https://www.sartorius.com/en
Photo -
https://mma.prnewswire.com/media/1696482/Sartorius.jpg
Logo -
https://mma.prnewswire.com/media/1696516/Sartorius_Logo.jpg
View original content to download
multimedia:https://www.prnewswire.com/news-releases/sartorius-significantly-expands-activities-in-south-korea-301432066.html
SOURCE Sartorius AG
